AK119

AK119 is a monoclonal antibody developed by Akeso. Its target is CD73 / adenosine axis (the sponsor names CD73). The sponsor states: AK119 is an anti-CD73 monoclonal antibody, studied in combination with AK112 for advanced solid tumours and colorectal cancer. ClinicalTrials.gov describes the intervention as: AK119 is an anti-CD73 monoclonal antibody. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in colorectal cancer. The largest, NCT05846867, plans to enrol 170 participants with primary completion expected 2026-05-08. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.